Hi [[ session.user.profile.firstName ]]

Medical Research

  • Is India Anywhere Closer to Implementing Continuous Bioprocessing
    Is India Anywhere Closer to Implementing Continuous Bioprocessing Narasimha Rao Nedunuri, CEO of CLONZ Biotech, and José Castillo, PhD, CTo and co-founder of Univercells Recorded: Aug 16 2018 66 mins
    Continuous processing has been widely employed in many biological manufacturing processes. In recent years it gained the momentum in the field of Biosimilar manufacturing due to an ever-increasing pressure for reduction in manufacturing costs.
    Potentially, the continuous processing offers Lower Cost of Goods, ease of scalability, and lower manufacturing footprint and hence became a topic of interest to many biosimilar players. Ongoing research on various new technologies for continuous operation, both in upstream and downstream processing may potentially be a game changer. Top on the wish list being, integration of all the multiple unit operations into a single continuous process with real time analytical tools.
    Though there are several challenges to develop and adapt continuous bioprocess, the magnitude of potential benefits are currently driving the research programs worldwide. India , being a significant global player in the biosimilar domain, currently making efforts to adapt these novel processes to make the drugs more cost effective.
  • Using sponsored research as a pathway to licensing early stage technologies
    Using sponsored research as a pathway to licensing early stage technologies Laura Schoppe, President and Owner of Fuentek Recorded: Aug 14 2018 46 mins
    Patent licensing negotiations have an extremely high fail rate- this can be down to unfavourable licensing terms or weak patent portfolios. One of the ways universities and industry are trying to bridge the gap between innovation and commercialisation is by working together much earlier.

    From a university standpoint, their research can be tailored to specific industry needs, as well as having research costs covered. Through the eyes of industry, they can get their hands on the latest research developments, and attract the brightest and talented individuals to their businesses.

    Laura Schoppe, President and Founder of Fuentek, who has years experience helping TTO's improve their chances of commercalisation will be joining us to discuss:

    - How to start sourcing strategic sponsorship deals
    - Where to begin with searching and conversations for partnerships
    - The benefits of this chosen pathway. i.e Minimising risk

    Please note: All viewers will have their data shared with our guest speaker.
  • The Impact of Artificial Intelligence in Medical Imaging
    The Impact of Artificial Intelligence in Medical Imaging Nadim Daher,Industry Principal, Siddharth Shah, Industry Analyst, Frost & Sullivan's Global Transformational Health Recorded: Aug 9 2018 56 mins
    Medical imaging has become a leader for the application of artificial intelligence technologies in the healthcare space, especially recently with deep learning techniques. This is evident from the fact that over 90 companies have set out to develop and commercialize AI-based solutions for the medical imaging industry. The number continues to grow as new start-ups emerge, as incumbents develop native AI solutions, and as tech companies move into the field, creating a highly dynamic ecosystem. With various countries edging past the innovator adoption phase and into the early adopter one, the time is now for stakeholders to refine and test their value proposition, partnership approach, and go-to-market strategies.

    Key Takeaways:
    • How far we have reached over the past five years and the current lay of the land
    • Where we are headed over the next five years and the direction of industry progress
    • Deep-dive into the opportunity for automation, acceleration and augmentation of medical image analysis
    • Anticipate the advent of intelligent medical imaging machines with embedded AI
  • IOP ebooks - Meet the author Professor Brian Diffey
    IOP ebooks - Meet the author Professor Brian Diffey Professor Brian Diffey Recorded: Aug 9 2018 45 mins
    Join us for this 45 minute webinar with the author of Sun Protection: A risk management approach, Professor Brian Diffey. Professor Diffey will give an overview of his book, key learning points and answer your questions in a live Q&A.

    About the book
    Sun Protection differentiates itself from other texts by adopting a risk-management approach to determine whether, how, and in what circumstances, harm might be caused, and to explore the feasibility of various strategies in controlling exposure to solar UV radiation. This multi-disciplinary book covers topics from climatology through human exposure to sunlight, as well as biological and clinical effects of UV radiation to physical and chemical strategies for photoprotection.

    This webinar is recommended viewing for biologists and dermatologists and will be of interest to physical scientists and those working in the skin care industry.
  • NASH Clinical Trials - Challenges and Considerations
    NASH Clinical Trials - Challenges and Considerations Dr. Andrew Roche, PhD, Scientific Director, Global Validation, Scientific Affairs, ICON Recorded: Jul 30 2018 47 mins
    Overview of current challenges associated with NASH Clinical Trials and examination of potential strategies to address during trial design or study execution.
  • Applications of Cryogenics: Past, Present, Future
    Applications of Cryogenics: Past, Present, Future Jorge Pelegrín Mosquera – Research Fellow at University of Southampton Recorded: Jul 27 2018 52 mins
    Air was first liquefied in 1877. Since then, the cooling power has been harnessed for many applications that have impacted science and society.

    In this webinar a review of the applications that cryogenics has enabled will be presented. From gas liquefaction to the use of cryocoolers in applications such as MRI scans, particle detectors, accelerators or fusion technology.

    Looking to the future of cryogenics, quantum-computing promises vastly increased computational power via the use of novel materials. Superconducting and cryogenic technologies offer cleaner, more efficient transport and power networks.
  • Subvisible Particles Matter, Developments in Regulations and Low Volume Methods
    Subvisible Particles Matter, Developments in Regulations and Low Volume Methods Dr Satish K Singh, Lonza Recorded: Jul 26 2018 69 mins
    The need to measure and characterize proteinaceous particles in therapeutic protein products has been emphasized by regulators. USP is a new chapter that addresses the limitations of USP for therapeutic proteins in measurement of subvisible particles. USP is a guidance chapter addressing the task of characterization of particles with the emphasis on proteinaceous particles. Furthermore, regulatory authorities require that sponsors understand the submicron particle size range of the products also. This article will look at latest regulatory developments, key aspects of the measurement of subvisible and submicron particles in biotherapeutics, as well as the utility of low volume methods.
  • How to create a 5-year M&A plan for dealing with patent cliffs
    How to create a 5-year M&A plan for dealing with patent cliffs Jurgen Vollrath, President at Exponential Technology Counsel Recorded: Jul 25 2018 40 mins
    A ‘Patent cliff’ describes a severe drop in revenue once the patent for a company’s leading product expires. The sharp revenue decline is a result of competitors being able to start developing and selling the product, often at a much lower price.

    As US biopharmaceutical company Celgene struggles to get regulatory approval from the FDA, the company is facing major market, shares and revenue losses, and is facing a phenomenal patent cliff. Furthermore, research from EvaluatePharma reports that an estimated $250 billion in projected sales is at risk between 2018-2024 as many drugs lose exclusivity.

    When it comes to acquisitions, the effects of a dwindling patent term can severely impact the value of your company. So how do you create 5-year plan to prepare for an inevitable patent cliff? We are very excited to welcome back Jurgen Vollrath, President of Exponential Technology Counsel, and customer of PatSnap. ET Counsel, advise clients on IP strategy & business alignment to ensure the most successful M&A and exit outcomes.

    In this webinar, Jurgen will be discussing:

    - Risk vs. reality when it comes to patent cliffs
    - How to create a 5-year M&A plan for your organisation
    - How to find potential acquisition targets
    - Predicting the potential impact a patent cliff could have on your business.
  • SUPERINSULATION – Heat Transfer and Influences on Insulation Performance
    SUPERINSULATION – Heat Transfer and Influences on Insulation Performance Holger Neumann – Divisional Head of Cryogenics of Institute for Technical Physics (ITEP) of KIT Recorded: Jul 25 2018 60 mins
    1. Introduction with motivation to the best kind of insulation for cryogenic applications
    2. Heat transfer mechanisms
    3. Description of MLI
    4. Heat transfer calculation
    5. Special influences on insulation performance like contact pressure, layer density, T-junctions
    6. Examples
  • High-Throughput Microfluidic Platform for Culture of 3D-Kidney Tissue Models
    High-Throughput Microfluidic Platform for Culture of 3D-Kidney Tissue Models Henriëtte Lanz, Ph.D. Recorded: Jul 24 2018 38 mins
    Drug toxicity remains a major issue in drug discovery and stresses the need for better predictive models. Here, we describe the development of a perfused renal proximal tubule cell (RPTC) model in Mimetas’ OrganoPlates® to predict kidney toxicity. The OrganoPlate® is a microfluidic platform, which enables high-throughput culture of boundary tissues in miniaturized organ models. In OrganoPlates®, ECM gels can be freely patterned in microchambers through the use of PhaseGuide technology. PhaseGuides define channels within microchambers that can be used for ECM deposition or medium perfusion. The microfluidic channel dimensions not only allow solid tissue and barrier formation, but also perfused tubular epithelial vessel structures can be grown. The goal of developing a perfused RPTC model is to reconstruct viable and leak-tight boundaries for performing cytotoxicity, as well as transport and efficacy studies. Human RPTC (SA7K clone, Sigma) were grown against an ECM in a 3channel OrganoPlate®, yielding access to both the apical and basal side. Confocal imaging revealed that the cells formed a tubular structure. Staining showed tight junction formations (ZO-1), cilia pointing into the lumen (acetylated tubulin) and correct polarization with microvilli on the apical side of the tubule (ezrin). Tightness of the boundary over several days was shown by diffusion of a dextran dye added to the lumen of the tubule. Addition of toxic compounds resulted in disruption of the barrier which could be monitored in time. The time point of loss of integrity corresponds with the concentration and the toxic effect of the compound. Furthermore, fluorescent transport assays showed functional transport activity of in- and efflux transporters. The 3D proximal tubules cultured in the OrganoPlate® are suitable for high-throughput toxicity screening, trans-epithelial transport studies, and complex co-culture models to recreate an in vivo-like microenvironment.
  • HPLC Method Development in One and a Half Days Using the Selectivity Concept
    HPLC Method Development in One and a Half Days Using the Selectivity Concept Dr. Frank Michel, Analytical & Chromatography Scientific Advisor, Merck KGaA, Darmstadt, Germany Recorded: Jul 24 2018 63 mins
    Modern HPLC technologies such as UHPLC, monolithic silica or Fused-Core™ particles provide superior separation efficiency and resolution of peaks. But in general resolution is more strongly impacted by selectivity which in turn can be affected by different stationary bonded phases. This presentation will discuss the choice of RP HPLC column chemistries such as RP-Amide, Phenyl, Pentafluorophenyl (F5) or Cyano which can provide alternative selectivities to traditional C18. It will compare their different retention mechanisms and highlight an approach to develop HPLC method within one and a half days.
  • Cryogenic Safety
    Cryogenic Safety Robert Done - Project design engineer - STFC - Rutherford Appleton Laboratory Recorded: Jul 23 2018 56 mins
    An introductory guide to the health and safety considerations required when using cryogenic equipment. The presentation will be based on the recently published fifth edition of the BCC cryogenic safety manual, will look at the legislation in place, and highlight some of the more significant hazards associated with cryogenics. The underlying theme will be a focus on reducing risks.
  • Introducing the CellStreamTM System, A Highly-Sensitive, 7-Laser Flow Cytometer
    Introducing the CellStreamTM System, A Highly-Sensitive, 7-Laser Flow Cytometer Robert Smith-Mccollum and Christine Probst Recorded: Jul 18 2018 40 mins
    MilliporeSigma is excited to launch the new CellStreamTM benchtop flow cytometry system, a highly-customizable, highly-sensitive 7-laser flow cytometer. Its unique optics system and design provides researchers with unparalleled sensitivity and flexibility when analyzing cells and submicron particles. Within the CellStreamTM system, the Amnis® time delay integration (TDI) and camera technology rapidly captures low resolution cell images and transforms them into high-throughput intensity data. Researchers acquire the intensity data they are accustomed to from traditional flow cytometers, but with greater fluorescence sensitivity. Join us in this webinar to take a deeper look inside the instrument design, system performance and software of this exciting new system.
  • Key components of a comprehensive program for the management of single use techn
    Key components of a comprehensive program for the management of single use techn John Maguire, Shire & Donald Young Thermo Fisher Recorded: Jul 18 2018 74 mins
    As a result of the increased adoption of single-use technologies (SUTs) in biotech manufacturing, companies need to develop and implement programmatic approaches for the management of these systems under regulatory compliance. This webinar discusses the key aspects of such programs, with emphasis on collaboration with suppliers, cost management, as well as practical insights about the use of SUTs.
  • Proficiency Testing Portal Training
    Proficiency Testing Portal Training Jennifer Duhon Recorded: Jul 12 2018 17 mins
    We have taken your feedback shared with us over the years and used this to help improve our service to you. With this new portal, you will find new features including your methods now saved as default, graphical reports, the option to trend your data, as well as the ability to expand and collapse your items on the data entry screen which will allow for quicker loading times. This presentation will go through each feature step by step. If you could like to skip straight to how to enter data, please go to slide 34.
  • How to accelerate your innovation pipeline using Social Impact Investments
    How to accelerate your innovation pipeline using Social Impact Investments Rosemarie Truman from The Center for Advancing Innovation Recorded: Jul 12 2018 45 mins
    Social Impact Investment brings together capital and experience from the public, private and non-for-profit industries to achieve specific social objectives. The return of these investments is measured typically by the social outcomes achieved.

    The Centre of Advancing Innovation is a public-private partnership non-profit focused on identifying breakthrough inventions hidden in portfolios, to maximise investor returns and commercial success. Research performed by the group has highlighted that Social Impact projects accelerate innovation, and result in higher returns.

    In this webinar, Rosemarie Truman, CEO and Founder of CAI will be discussing the positive implications of choosing social impact projects for your business, including:

    - Why they accelerate innovation
    - How these projects can increase your potential investment opportunities for the future
    - The influence on the future funding of projects.
  • Development and Manufacturing of Recombinant Nanoparticle Vaccines
    Development and Manufacturing of Recombinant Nanoparticle Vaccines Atin Tomar, President of CPL Biologicals & Amelie Boulas Of Sartorius Stedim Recorded: Jul 12 2018 67 mins
    A recombinant vaccine technology platform based on highly purified, properly-folded protein antigens in stable well-defined Nanoparticles, enabling efficient and safe manufacture of vaccines against highly pathogenic targets. Nanoparticles are intrinsically immunogenic, producing both durable neutralizing antibodies and cellular immunity. The platform can be utilized for rapid response to potential pandemics as the time from identification of relevant viral gene sequence to final GMP drug product ready for human studies has been demonstrated to take less than 4 months for multiple vaccines.
    The GMP drug substance manufacturing process for the platform largely utilizes single-use technologies. Single-use-technologies and recombinant platform enables the utilization of same manufacturing facility for multiple products with rapid change-over.
  • Raman spectroscopy measurements during Bioprocessing
    Raman spectroscopy measurements during Bioprocessing Nobel Vale, Research Scientist II, Bristol-Myers Squibb and Justin Moretto, Bioprocessing Consultant, Kaiser Optical Systems, Recorded: Jul 11 2018 78 mins
    Raman spectroscopy has been seen as spectroscopic tool used in bioprocessing to monitor and control cell metabolism to optimize quality and yield of titer. This is due to Raman’s insensitivity to water and ability to analyze samples without manipulation. However there are certain challenges for Raman when analyzing a complex and dynamic sample such as a cell culture. This article will describe the different challenges in analyzing in-line Raman data and how to mitigate changes in samples that include changes in fluorescence background, presence of cells/debris in samples, and spectral interference.
  • Object Storage. What it Solves & Why it’s Better for Your Data at Scale.
    Object Storage. What it Solves & Why it’s Better for Your Data at Scale. Mike McWhorter, Senior Technologist, Western Digital Recorded: Jul 10 2018 25 mins
    Most have heard about object storage, but what problem is it solving, and how does it compare to other storage solutions like SAN or NAS? If these are questions you’ve asked yourself this webinar is for you! (Hint: The problem Object Storage solves is scalability.)

    Join Senior Technologist Mike McWhorter as he explains how Object Storage differs from SAN, NAS and distributed file systems, the unique technological features which make object storage ideal for archiving, accessing or protecting data (especially unstructured data), and how different industries are using Object Storage today.

    Register today to watch live or for the on-demand recording.
  • Proficiency Testing Portal Training
    Proficiency Testing Portal Training Jennifer Duhon Recorded: Jul 10 2018 17 mins
    We have taken your feedback shared with us over the years and used this to help improve our service to you. With this new portal, you will find new features including your methods now saved as default, graphical reports, the option to trend your data, as well as the ability to expand and collapse your items on the data entry screen which will allow for quicker loading times. This presentation will go through each feature step by step. If you could like to skip straight to how to enter data, please go to slide 34.
  • Soft Tissue Cancer & IHC
    Soft Tissue Cancer & IHC Jeff Gordon Recorded: Jun 29 2018 65 mins
    Soft tissue tumors are a broad group of neoplasms that involve the connective tissue of the body. Each year, over 13,000 people in the US are diagnosed with soft tissue sarcomas and over 5,000 people succumb to the malignancy. Because soft tissue sarcomas are very ambiguous and amorphous, many time sarcomas are classified as an uncertain type. Advances in immunohistochemistry as well as the utility of novel markers such as TFE3, TLE1, MyoD1, and MUC4 have aided pathologists in classifying these soft tissue tumors. This discussion will cover the key facts and statistics about soft tissue tumors and what role IHC plays in these difficult diagnoses.
  • Multiplexed immunofluorescence and digital image analysis for clinical use
    Multiplexed immunofluorescence and digital image analysis for clinical use Mehrnoush Khojasteh, PhD & Lei Tang, PhD Recorded: Jun 28 2018 63 mins
    There is an ever increasing need to understand the role of the Tumor Microenvironment (TME) in Cancer Immunotherapy. In this webinar, Drs. Lei Tang, PhD and Mehrnoush Khojasteh,PhD of Roche Tissue Diagnostics (Ventana Medical Systems, Inc.), present their work on multiplex immunofluorescence staining and digital pathology analysis in a CAP/CLIA certified laboratory. Multiplexed immunohistochemistry (IHC) enables the spatial characterization of TME immune cells and tumor cells by detecting multiple biomarkers while preserving tissue morphology. Co-expression of multiple biomarkers and relative spatial relationships requires whole slide digital pathology image analysis algorithms that are tailored to individual assays and their intended uses. The process described in this presentation demonstrates how multiplexing and digital pathology enable biotech and pharmaceutical research and development teams to explore the potential medical value of specific biomarkers,
  • CRISPR Protein Products
    CRISPR Protein Products Yanfang Jiang, Ph. D. Recorded: Jun 28 2018 32 mins
    MilliporeSigma is a pioneer in commercially offering targeted genome editing tools. With its 14-year experience in the first generation of genome editing tools such as TargeTron® and Zinc Finger Nuclease, MilliporeSigma has emerged as a prominent leader in the development of CRISPR systems, the most flexible and efficient genome editing technology thus far developed. CRISPR-based DNA integration patents have been granted to MilliporSigma in seven regions including Australia, Canada, the European Union, Singapore, Israel, South Korea, and most recently in China. The MilliporeSigma CRISPR portfolio consists of an array of CRISPR products, in both the plasmid, RNA, protein, and lentiviral formats. MilliporeSigma is also the first commercial provider to offer both pooled and arrayed whole human genome CRISPR libraries.

    In this webinar, we will give an introduction to our current CRISPR protein products, including SpCas9 (CAS9PROT), Cas9-D10A nickase (CAS9D10APR), high fidelity eSpCas9 (ESPCAS9POR), catalytically inactive dCas9-FLAG-biotin (DCAS9PROT), and FnCas9 (FNCAS9PROT), focusing on specific enzyme characteristics of each protein and their potential applications for the research community.
  • Strategies to overcome Low Endotoxin Recovery using the conventional LAL assay
    Strategies to overcome Low Endotoxin Recovery using the conventional LAL assay Dr. Ruth Daniels, Janssen & Kevin L. Williams, BIOMÉRIEUX USA, Inc. Recorded: Jun 28 2018 63 mins
    Title: Strategies to overcome Low Endotoxin Recovery using the conventional LAL assay
    Presenter: Dr. Ruth Daniels, Janssen
    This presentation will discuss:
    - Endotoxin hold time studies to identify LER
    - In silico assessment of interfering factors and associated LER mitigation strategies
    - Case study: optimization of product-specific LAL assay to overcome LER

    Title: : Addressing LER at the root, with ENDO-RS® sample preparation (demasking) prior to endotoxin assay of choice
    Presenter: Kevin L. Williams, Senior Scientist Endotoxin - BIOMÉRIEUX
    Scientific studies have demonstrated that biologics typically containing protein in high concentrations and non-ionic surfactants, are likely to change the aggregate state of endotoxin in such a way that it is no longer accessible for detection with Factor C-based endotoxin detection methods (LAL and rFC). The ENDO-RS® endotoxin recovery method developed by Hyglos - a bioMérieux company, is a unique toolbox of dedicated reagents for demasking (recovering) endotoxin prior to detection, also for conventional LAL. This presentation covers the mechanism of LER, regulatory requirements, work principle of ENDO-RS, the demasking services of bioMérieux, as well as method application data.